Sulfisoxazole

Summary

Sulfisoxazole (CHEMBL453) is an approved small-molecule antibacterial drug (ATC J01EB05); indicated across 3 conditions including bacterial infectious disease and eye infectious disorder.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: J01EB05 (+1 more)
• Indications: 3 conditions
• Chemistry: 267.31 Da · C11H13N3O3S

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL453
Name	Sulfisoxazole
Type	Small molecule
Max phase	4
FDA approved	no
PubChem CID	5344
ChEBI	CHEBI:102484
ATC	J01EB05, S01AB02
Molecular formula	C11H13N3O3S
Molecular weight	267.31
InChIKey	NHUHCSRWZMLRLA-UHFFFAOYSA-N

SMILES: CC1=C(ON=C1C)NS(=O)(=O)C2=CC=C(C=C2)N

IUPAC name: 4-amino-N-(3,4-dimethyl-1,2-oxazol-5-yl)benzenesulfonamide

ChEBI definition: A sulfonamide antibacterial with an oxazole substituent. It has antibiotic activity against a wide range of gram-negative and gram-positive organisms.

Pharmacological roles (ChEBI): antibacterial drug, drug allergen.

Also known as: Entusil, Eryzole, Gantrisin, NSC-13120, NSC-683536, Neazolin, Pediazole, Sosol, Soxazole, Sulfafurazol, Sulfafurazole, Sulfalar

Parent form; salt/anhydrous children: CHEMBL1200321

Patent coverage: 5,841 distinct patent families (21,363 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 8 (assay-derived). Sample: Endothelin receptor type B, Thyrotropin receptor, Menin/Histone-lysine N-methyltransferase MLL, Alpha-1A adrenergic receptor, Endothelin-1 receptor, Cytochrome P450 2C9, Cytochrome P450 2C19, Endothelin-1 receptor.

Bioactivity

ChEMBL activities: 14 potent at pChembl ≥ 5 of 22 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
CYP2C19	8.2	Potency	6.3	nM	CHEMBL_ACT_4020194
CYP2C19	8.2	AC50	6.31	nM	CHEMBL_ACT_6039803
TSHR	6.4	Potency	398.1	nM	CHEMBL_ACT_3935457
TSHR	6.4	Potency	398.1	nM	CHEMBL_ACT_4699345
EDNRA	6.22	IC50	600	nM	CHEMBL_ACT_29171069
EDNRA	6.11	IC50	780	nM	CHEMBL_ACT_1115501
EDNRA	6.11	IC50	780	nM	CHEMBL_ACT_469073
P26684	6.11	IC50	780	nM	CHEMBL_ACT_481516
TSHR	6.1	Potency	794.3	nM	CHEMBL_ACT_3914295
TSHR	6.1	Potency	794.3	nM	CHEMBL_ACT_4691163
P26684	6.1	IC50	800	nM	CHEMBL_ACT_496660
EDNRA	6.07	IC50	850	nM	CHEMBL_ACT_261304
MEN1	5.15	Potency	7080	nM	CHEMBL_ACT_3619873
P26684	5.05	IC50	9000	nM	CHEMBL_ACT_173040

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

3 indications (2 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
bacterial infectious disease	4	MONDO:0005113	EFO:0000771
eye infectious disorder	4	MONDO:0043885	EFO:1001888
osteomyelitis	0	MONDO:0005246	EFO:0003102

Clinical trials

Total trials: 0.

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

PharmGKB dosing guidelines (1) — CPIC / DPWG genotype-guided dosing for this drug (drug × pharmacogene):

Guideline	Source	Gene(s)	Dosing	Recommendation
Annotation of CPIC Guideline for aminosalicylic acid, chloramphenicol,	CPIC	G6PD

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).